Observation of Efficacy and Safety of Ositinib Plus Bevacizumab in First-line Treatment of Patients with Advanced NSCLC with EGFR T790M Mutation
Objective To investigate the efficacy and safety of osimertinib combined with bevacizumab in patients with EGFRT 790M mutated advanced non-small cell lung cancer(NSCLC).Methods A total of 82 patients with EGFR T790M muta-tion advanced NSCLC were selected and divided into 2 groups according to odd and even number.41 patients in the control group were treated with osimertinib and 41 patients in the study group were treated with osimertinib combined with bevacizumab.After 4 cycles of treatment,the efficacy and safety of the 2 groups were evaluated.Results After treatment,the objective remission rate(ORR),disease control rate(DCR)and T lymphocyte subsets(CD3+,CD4+,CD4+/CD8+)levels in the study group were higher than those in the control group(P＜0.05).The levels of carcinoembryonic antigen(CEA),human cytokeratin 21-1(cy-fra21-1)and carbohydrate antigen CA125(CA125)in the study group were lower than those in the control group(P＜0.05).The adverse reactions such as anemia,rash,liver function damage,gastrointestinal reactions,proteinuria and hypertension in the 2 groups were graded as 1-2,and the difference was not statistically significant(P＞0.05).Conclusion Osimertinib combined with bevacizumab as first-line treatment for advanced NSCLC with EGFR T790M mutation can improve the immune function of pa-tients,reduce the level of tumor markers,with high clinical efficacy and good safety.
OsimertinibBevacizumabEGFR T790M mutationNon-small cell lung cancer
万方数据
维普
